Matching to our in vitro findings, analysis of the GBM spatial transcriptomics data revealed a positive correlation between the expression of the BCL-xL and the activation of the MAPK-pathway within patient tumour samples (Fig. 4F). The gene discussed is BCL2L1; the disease is neoplasm.